WHAT IS IXIARO®?
IXIARO® is a vaccine (inactivated, adsorbed) that helps protect against Japanese encephalitis (JE).1
It is the only licensed and recommended vaccine available in the UK to help protect travellers against JE.2
IXIARO® INDICATION
IXIARO® is indicated for active immunisation against Japanese encephalitis in adults, adolescents, children, and infants aged two months and older.1
IXIARO® should be considered for use in individuals at risk of exposure through travel or their occupation.1
IXIARO® CONTRAINDICATIONS
IXIARO® should not be administered to individuals with hypersensitivity to the active substance, any of the excipients, or to residual substance.1
Individuals who show hypersensitivity reactions after receiving the first dose of the vaccine should not be given the second dose.1
IXIARO® is not recommended for those who are pregnant or lactating.1
Administration should also be postponed in individuals with acute severe febrile illness.1
IXIARO® KEY FACTS
EFFICIENT PROTECTION
Can offer efficient protection against JE from infancy to adulthood.1
SUITABLE FOR LAST-MINUTE TRAVEL
For adult travellers aged 18–65, both doses can be administered just seven days apart for last-minute protection.1
LONG-TERM PROTECTION
A booster dose gives travellers a decade of protection.1
GENERALLY WELL TOLERATED
Generally well tolerated across all ages, supported by over 16 years of real-life experience.1,3
STRAIGHTFORWARD TO ADMINISTER
Supplied in a ready-to-use syringe for administration.1
PRODUCT CHARACTERISTICS
IXIARO® is a purified and inactivated JEV vaccine. The virus is grown in Vero cells, purified, inactivated, and then adsorbed on aluminium hydroxide.1,4 The final vaccine is in the form of a suspension in a pre-filled syringe. Each unit dose of IXIARO® contains inactivated Japanese encephalitis virus strain SA14–14–2 (inactivated) 6 AU corresponding to a potency of ≤460 ng ED50.1
The vaccine does not contain any preservative or stabilisers.5
VACCINE STORAGE AND HANDLING
IXIARO® should be stored in a refrigerator at 2–8°C in its original packaging to protect from light.1
It has a shelf life of three years.1
LEARN MORE ABOUT IXIARO®
Delve deeper into the product features, clinical findings and dosing recommendations.
IXIARO® suspension for injection
CLINICAL DATA
Explore the latest clinical data on the efficacy and safety profile of IXIARO®.
IXIARO® suspension for injection
DOSING & ADMINISTRATION
IXIARO® is administered in two doses for adults and children >2 months.
References
- IXIARO®. Summary of Product Characteristics. March 2023. Available at: https://www.medicines.org.uk/emc/product/6534. Accessed: August 2026.
- UK Health Security Agency. Japanese encephalitis: the green book, chapter 20. February 2024. Available at: https://www.gov.uk/government/publications/japanese-encephalitis-the-green-book-chapter-20. Accessed: August 2026.
- Yun SI, Lee YM. Japanese encephalitis: the virus and vaccines. Hum Vaccin Immunother. 2014;10(2):263-279.
- Firbas C, Jilma B. Product review on the JE vaccine IXIARO. Hum Vaccin Immunother. 2015;11(2):411-420.
- Dubischar-Kastner K, Kaltenboeck A, Klingler A, Jilma B, Schuller E. Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine, IXIARO® (IC51), in 6 months of follow-up. Vaccine. 2010;28(39):6463-6469.
UK-IXI-2600001 (v2.0) August 2026